• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Critical Congenital Heart Disease 
    • 25% of Congenital Heart Disease is considered “critical”
    • Diagnosis now relies on prenatal diagnosis or neonatal signs and symptoms
    • Delayed diagnosis of CCHD causes increased morbidity and mortality 
    Pulse Oximetry Screening
    • Pulse Ox screening of newborns can improve the detection of CCHD when combined with a thorough examination.
    • Pulse Ox Screening may be performed by a health professional whose scope of practice includes pulse oximetry.
    • All babies should be screened prior to discharge from care.
    • Pulse Oximetry machines should be approved for neonates and motion-tolerant machines are ideal.
    • Pre and Post-ductal saturations should be obtained from the right hand and one foot.
    • For the quick guide to screening interpretation click here.
    • If the screen is abnormal the baby must be evaluated by the attending clinician.
    For additional information on Pulse Oximetry Screening please click on the following links :
    Documenting Screening Results
    • Screening results should be entered into the Oz database.
    • For additional information on how to document into the Oz Database CIick Here:
    Screening Protocols
    Each hospital or birthing center must have established protocols for performing pulse oximetry screening, as well as following up on abnormal screens and babies who are not screened prior to discharge.  Protocols should address the following questions:
    1. Who will screen and when?
    2. Who will be notified of the abnormal screening results?
    3. How will the baby be evaluated after an abnormal screening result?
    4. Who will enter the data into the electronic database?
    5. What is your follow up plan in the event a baby is discharged without a screening?